• LAST PRICE
    0.2793
  • TODAY'S CHANGE (%)
    Trending Up0.0093 (3.4444%)
  • Bid / Lots
    0.2749/ 7
  • Ask / Lots
    0.2900/ 42
  • Open / Previous Close
    0.2710 / 0.2700
  • Day Range
    Low 0.2700
    High 0.2899
  • 52 Week Range
    Low 0.1866
    High 1.3400
  • Volume
    30,837
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.27
TimeVolumeKZIA
09:32 ET1700.271
09:36 ET10000.27985
09:38 ET1000.28
09:45 ET122340.2899
10:03 ET7970.28
10:10 ET2000.284
10:44 ET2000.285
10:53 ET2000.28
11:02 ET10000.27975
11:04 ET19570.28
11:06 ET12450.28
11:15 ET1250.2823
11:18 ET10000.2824
11:22 ET3870.2822
11:29 ET3070.28
11:38 ET1000.28
12:02 ET1000.276
12:21 ET2000.275
12:36 ET1000.27
12:52 ET2000.2749
01:35 ET1000.2798
02:22 ET9600.2749
02:38 ET1000.27
03:21 ET1000.2793
03:39 ET3000.2793
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKZIA
Kazia Therapeutics Ltd
7.4M
-0.3x
---
United StatesCING
Cingulate Inc
4.9M
0.0x
---
United StatesPKTX
ProtoKinetix Inc
4.9M
-11.6x
---
United StatesGBLX
GB Sciences Inc
4.8M
-1.1x
---
United StatesPRTG
Portage Biotech Inc
5.2M
0.0x
---
United StatesARTL
Artelo Biosciences Inc
4.6M
-0.5x
---
As of 2024-05-26

Company Information

Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.

Contact Information

Headquarters
Three International Towers Level 24 , 300 Barangaroo AvenueSYDNEY, NSW, Australia 2000
Phone
---
Fax
---

Executives

Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
John Friend
Chief Financial Officer
Karen Krumeich
Clinical & Regulatory Affairs Manager
Lilischkis Kimberley
Chief Business Officer
Peng Leong
Program Director - Degenerative Diseases
Stephen Palmer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.4M
Revenue (TTM)
$15.0K
Shares Outstanding
13.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.06
EPS
$-0.82
Book Value
$0.35
P/E Ratio
-0.3x
Price/Sales (TTM)
492.5
Price/Cash Flow (TTM)
---
Operating Margin
-91,918.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.